Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6178 pages
Showing 551 - 600Prolonged Use of Progestogens May Be Linked to Increased Risk of Brain Cancer
Prolonged use of selected progestogen agents may be associated with an increased risk of developing intracranial meningioma, according to a recent study published by Roland et al in the BMJ. Background Progestogens are similar to the natural hormone progesterone, which are widely used in menopausal ...
Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer
Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...
IKZF1 Genetic Variant May Contribute to Disparities in Risk of ALL in Pediatric Hispanic and Latino Patients
A genetic variant located on the IKZF1 gene may be responsible for disparities in the risk of acute lymphoblastic leukemia (ALL) among Hispanic and Latino children, according to a recent study published by de Smith et al in Cell Genomics. The findings offer insights into the causes of the disease...
Novel Drug Combination in Multiple Myeloma
Researchers have found that venetoclax in combination with azacitidine may be effective at treating patients with multiple myeloma, according to a recent study published by Flanagan et al in Haematologica. Background Despite recent advances in the treatment of multiple myeloma, the disease remains ...
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy
Matthew A. Powell, MD, of the Washington University School of Medicine, discusses phase III findings from the RUBY trial, which shows dostarlimab-gxly plus chemotherapy improves overall survival in patients with primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. ...
Gut Microbiome Signatures May Help Unravel Disparities in Early-Onset Colorectal Cancer
The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer, according to a recent study published by Hein et al in the Journal of Immunotherapy and Precision Oncology. The findings provide insights into...
Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes
Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...
Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA
Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy...
Dostarlimab-Based Combinations in Advanced Endometrial Cancer
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...
FDA Approves Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic ...
Low-Dose Radiotherapy Boost in Young Patients With Breast Cancer
Researchers have found that a low-dose radiotherapy boost in addition to whole-breast radiotherapy may prevent local recurrence in young patients with breast cancer, according to new findings presented by Bosma et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 4LBA) and...
Response to Primary Systemic Therapy Could Dictate Whether Extensive Lymph Node Removal Is Needed in Patients With Breast Cancer
Extensive removal of the lymph nodes may be safely avoided in patients with breast cancer that has metastasized to the axillary nodes if treatment is tailored to their response to therapies such as chemotherapy prior to surgery, according to new findings presented by van Hemert et al at the 2024...
Combined PET-MRI Scan Could Benefit Patients With Early-Stage Breast Cancer
A combined positron-emission tomography–magnetic resonance imaging (PET-MRI) scanning technique could improve the treatment of some patients with early-stage breast cancer, according to new findings presented by Di Micco et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 9) and...
Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before...
FDA Approves Safety Labeling Changes Regarding DPD Deficiency for Fluorouracil Injection Products
On March 21, the U.S. Food and Drug Administration (FDA) approved safety labeling changes for fluorouracil injection products. This effort was a collaboration between the FDA’s Office of Generic Drugs and the Oncology Center of Excellence. Fluorouracil injection was initially approved in 1962. The...
Addition of Atezolizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of atezolizumab to postsurgery chemotherapy may not benefit patients with triple-negative breast cancer, according to findings recently presented by McArthur et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1LBA). Background Triple-negative breast cancer is often...
Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer
Taking part in an exercise program may improve pain, fatigue, and quality of life in patients with metastatic breast cancer, according to recent findings presented by Hiensch et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1). Background “Although there’s been quite a lot of...
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...
Updated Immune Classifier May Accurately Identify Patients With Triple-Negative Breast Cancer Who Are Unlikely to Respond to Immunotherapy
A novel genetic test may predict how patients with triple-negative early-stage breast cancer will respond to immunotherapy, according to new findings presented by Wolf et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA). The research may help patients who are unlikely to...
Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...
W. Kimryn Rathmell, MD, PhD, Selected as 17th Director of the NCI
W. Kimryn Rathmell, MD, PhD, took the helm as the 17th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on December 18, 2023. A renowned kidney cancer expert and influential leader in cancer research and patient care, Dr. Rathmell was selected by...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Cancer Care Providers Urge President Biden to Make Health Care a State of the Union Priority
In a news release issued by ASCO earlier this month, the society reported that The Association for Clinical Oncology (ASCO) was calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. Specifically, the cancer care...
Use of Combination Immunotherapy Before Lung Cancer Surgery
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center,...
Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy
Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...
Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib
Mansoor R. Mirza, MD, of Copenhagen University Hospital, discusses follow-up results from the RUBY trial, showing that, for patients with primary advanced or recurrent endometrial cancer, dostarlimab-gxly plus chemotherapy followed by dostarlimab-gxly plus niraparib improved progression-free...
Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as...
FDA Grants Accelerated Approval to Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the multitarget kinase inhibitor (Iclusig) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). PhALLCON Efficacy was evaluated in...
Lillian L. Siu, MD, FRCPC, FASCO, FAACR, Named 2024–2025 AACR President-Elect
The American Association for Cancer Research (AACR) announced that its members have elected Lillian L. Siu, MD, FRCPC, FASCO, FAACR, as the 2024–2025 President-Elect of the AACR. Professional and Research Background Dr. Siu currently serves as Professor of Medicine at the University of Toronto; as ...
Hormonal Therapy Plus SBRT for Advanced Prostate Cancer
Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus...
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair–proficient (pMMR) advanced or ...
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...
Exploring the Genetic Link Between Colorectal Cancer and Meat Consumption
Researchers have identified two genetic markers that may illuminate the association between red and/or processed meat consumption and the risk of colorectal cancer, according to a novel study published by Stern et al in Cancer Epidemiology, Biomarkers & Prevention. Background Previous studies...
Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...
FDA Approves Tislelizumab for Previously Treated Patients With Advanced Esophageal Cancer
On March 14, the U.S. Food and Drug Administration (FDA) approved the humanized immunoglobulin G4 anti–PD-1 monoclonal antibody tislelizumab-jsgr (Tevimbra) as monotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not...
Trends in Breast Cancer Diagnoses During the COVID-19 Pandemic
Investigators may have identified a decrease in newly diagnosed breast cancer cases during the first year of the COVID-19 pandemic, according to a recent study published by Fefferman et al in Cancer Medicine. The findings highlight that breast cancer was not immune to pandemic-related stressors and ...
ACS and Flatiron Health Announce Recipients of Fourth Annual Real-World Data Impact Awards
The American Cancer Society (ACS) and Flatiron Health announced the recipients of the 2023 Real-World Data Impact Awards, which will support clinically relevant research regarding the treatment of and outcomes for patients with cancer. 2023 marks the fourth year of the joint grant-making program,...
Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma
Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...
Germ Cell Tumors: Survival Rates in Female vs Male Patients
Female patients with ovarian germ cell tumors may have worse prognoses compared with male patients with testicular germ cell tumors, according to a recent study published by Sköld et al in the Journal of Internal Medicine. Background Both ovarian and testicular germ cell tumors predominantly...
Risk Score to Assess Cardiovascular Complications in Hematopoietic Stem Cell Transplant Recipients
A novel tool may help predict the risk of complications following hematopoietic stem cell transplantation and guide the pretransplant process, according to new Scientific Statement published by Hayek et al in Circulation. The findings may also illuminate the contemporary prevalence of...
Collaborative Care Intervention May Benefit Patients With Cancer, Health-Care Systems
Adding specialized mental health support to the treatment plan of patients with cancer may improve their quality of life, lower the risk of cardiovascular disease in family caregivers, and boost cost savings to the health-care system, according to a recent study published by Steel et al in The...
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis
A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction
Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...
Patricia LoRusso, DO, PhD (hc), Named the Amy and Joseph Perella Professor of Medicine at Yale School of Medicine
Patricia LoRusso, DO, PhD (hc), an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies, was recently appointed the Amy and Joseph Perella Professor of Medicine (medical oncology). The appointment is for a term of 10 years,...
ACCC Changes Name to Association of Cancer Care Centers
The Association of Community Cancer Centers (ACCC) is marking its 50th anniversary with a name change to illustrate the dynamic future of cancer care for its members. The largest advocacy and resource organization for multidisciplinary oncology professionals will now be known as the Association of...
Geriatric Oncology Educational Opportunity at Memorial Sloan Kettering Cancer Center
Once again, geriatric oncology will take the forefront at Memorial Sloan Kettering (MSK). On April 23, 2024, the Division of Advanced Practice Providers and the Geriatric Medicine Service at MSK will host the 3rd annual Geriatric Oncology Symposium for Advanced Practice Providers. The target...
Five New Cancer Grand Challenges Teams Named in Global Effort to Resolve Hurdles in Cancer Research
The Cancer Grand Challenges initiative announced it has selected five new global teams that will each receive up to $25 million in funding over the course of 5 years to address four major challenges faced by cancer research. Background In March 2023, the initiative unveiled nine new challenges to...
